Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $14.00.

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Chardan Capital started coverage on shares of Kalaris Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target on the stock. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp assumed coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday.

Kalaris Therapeutics Trading Up 0.2%

Shares of Kalaris Therapeutics stock opened at $9.80 on Friday. The company’s fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $5.45. The company has a market cap of $183.26 million, a P/E ratio of -2.60 and a beta of -0.09. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Trading of Kalaris Therapeutics

Hedge funds have recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $58,000. XTX Topco Ltd bought a new stake in Kalaris Therapeutics during the second quarter valued at approximately $65,000. Bridgeway Capital Management LLC bought a new position in Kalaris Therapeutics in the third quarter worth approximately $130,000. Belpointe Asset Management LLC bought a new position in Kalaris Therapeutics in the third quarter worth approximately $231,000. Finally, Fortis Capital Advisors LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter worth $231,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.